Alpha-methylacyl-CoA racemase (AMACR) is an
enzyme playing an important role in the beta-oxidation of branched-chain
fatty acids and
fatty acid derivatives. High expression levels of AMACR have been described in various
cancers, including
prostate cancer,
colorectal cancer and
kidney cancer. Because of its
cancer-specific and frequent expression, AMACR could be an attractive target for cytotoxic T-lymphocyte (CTL)-based
immunotherapy for
cancer. In the present study, we examined the induction of AMACR-specific CTLs from
prostate cancer patients' peripheral blood mononuclear cells (PBMCs) and determined HLA-A24-restricted CTL
epitopes.RT-PCR and immunohistochemical analysis revealed that AMACR was strongly expressed in
prostate cancer cell lines and tissues as compared with benign or normal prostate tissues. Four AMACR-derived
peptides carrying the HLA-A24-binding motif were synthesized from the amino acid sequence of this
protein and analyzed to determine their binding affinities to
HLA-A24. By stimulating patient's PBMCs with the
peptides, specific CTLs were successfully induced in 6 of 11 patients. The
peptide-specific CTLs exerted significant cytotoxic activity against AMACR-expressing
prostate cancer cells in the context of
HLA-A24. Our study demonstrates that AMACR could become a target
antigen for
prostate cancer immunotherapy, and that the AMACR-derived
peptides might be good
peptide vaccine candidates for HLA-A24-positive AMACR-expressing
cancer patients.